
Dr. Denise Yardley leading a standing-room only session on ‘GLP-1/Cancer’ at #McKessonAccelerate #CommunityOncology @SarahCannonDocs Interesting early observations - Important research ahead

President and Chief Medical Officer at Sarah Cannon Research Institute | Advancing Therapies Through Clinical Research #Oncology #Healthcare #CancerResearch

Dr. Denise Yardley leading a standing-room only session on ‘GLP-1/Cancer’ at #McKessonAccelerate #CommunityOncology @SarahCannonDocs Interesting early observations - Important research ahead

Looking back at #ESMO2026: SCRI investigators contributed 85+ abstracts and presentations, w/ 3 Phase III studies featured in the Presidential Symposium & published simultaneously in @TheLancet or @NEJM. Thanks to the teams & pts advancing cancer research. scri.com/news/scri-esmo-2026…


Fantastic discussion!
🎯 #ESMO26 | Excellent discussion by @benlevylungdoc on SARON and PERSEE! Two trials, two important lessons for advanced NSCLC. 🔹 SARON: Consolidative radiotherapy improved PFS and local disease control in oligo metastatic NSCLC, but no OS benefit (HR 0.99). 🔹 PERSEE: Pembrolizumab + chemo met its primary endpoint PFS but not OS though numerically better (not powered for OS) in PD-L1 ≥50% NSCLC. Key messages from @benlevylungdoc : • Oligometastatic disease needs better biological definition, beyond the number of lesions. • Treatment intensification should be guided by better patient selection. • More treatment does not automatically mean better outcomes! - Lower threshold to add chemo to pembro in PD-L1 >50% 👏 A thoughtful discussion with practical implications for our clinics. #ESMOAmbassador #LungCancer #NSCLC

Outstanding presentation by our very own @DanaFarber @sands_jacob ! DeLLphi-305: tarlatamab + durvalumab vs durvalumab as 1L maintenance in ES-SCLC improved median OS to 21.1 vs 12.7 months (HR 0.42). A major advance for patients with SCLC! #ESMO26 @oncoalert @myESMO

Presented at #ESMO26: Among patients with PD-L1–negative advanced nonsquamous non–small-cell lung cancer, progression-free survival was longer with sacituzumab tirumotecan plus pembrolizumab than with chemotherapy plus pembrolizumab (15.0 vs. 5.7 months). Full phase 3 OptiTROP-Lung06 trial results: nej.md/4Bo3liu @myESMO

At #ESMO26, SCRI will present 85+ abstracts and presentations across antibody drug conjugates, immunotherapies, and bispecific antibodies, with work from 40 authors across our network of research sites. scri.com/news/sarah-cannon-r…

Presented at #ESMO26: In patients with previously treated advanced non–small-cell lung cancer with a 𝘒𝘙𝘈𝘚 G12C mutation, median progression-free survival was 9.8 months with the KRAS G12C inhibitor divarasib and 5.7 months with sotorasib or adagrasib. Full phase 3 Krascendo 1 trial results: nej.md/4BiCvbk @myESMO

Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for patients with KRAS G12C-mutated lung cancer. scri.com/news/sarah-cannon-r…

Expanding access to clinical trials remains a critical priority in oncology research. @SPremji7866 of SCRI recently shared insights with @TargetedOnc on the importance of community-based research and the evolving breast cancer landscape. targetedonc.com/view/dr-prem…

Congratulations to @IMFmyeloma on the launch of the US Myeloma Network! We are honored to serve as the CRO and support clinical trials designed to advance research and expand opportunities for patients w/ multiple myeloma. Looking forward to this collaboration in #CancerResearch.
I am proud to announce the launch of the US Myeloma Network (USMN) by the International Myeloma Foundation. @IMFmyeloma The USMN will conduct clinical trials including phase III randomized controlled trials. @JNJInnovMed is our first industry partner. @SarahCannonDocs will be our CRO. @SagarLonialMD @TomMartinMD @szusmani @myelomaMD @NikhilMunshiMD prnewswire.com/news-releases…

In a recent interview w/ @Blood_Cancers, Dr. Hans Lee of @SCRIOncology discusses how cellular therapies are changing care for patients with advanced multiple myeloma and the importance of expanding access. Read the Q&A:
The next step in advanced #myeloma is improving access to therapies such as CAR-T and bispecific antibodies, according to Hans Lee, MD, of @SarahCannonDocs. 📖 Read more from this exclusive Q&A: buff.ly/5qX7rQu

Breaking from #ASCO26: The Phase 3 #frontMIND trial successfully hit its primary endpoint! 🚨 Adding tafasitamab + lenalidomide to standard R-CHOP significantly improves PFS in newly diagnosed high-risk #DLBCL. Full story: bit.ly/3REcctU

What research is generating buzz heading into #ASCO26? In a new @biospace feature, Dr. @MeredithPelster of Sarah Cannon Research Institute shares insights on promising advances in pancreatic cancer research and targeted therapies. biospace.com/drug-developmen…

Inspiring discussion around how we can have greater impact in the community for veterans w/ our colleagues at #FCS & the VA @Dee_Anna_Smith @LucioGordanMD #ASCO26

Meet SCRI experts at #ASCO26 for a lymphoma session led by @KrishPatelMD . Join the conversation and learn how we are advancing research for patients.